Literature DB >> 9647246

Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.

M R Roberts1, K S Cooke, A C Tran, K A Smith, W Y Lin, M Wang, T J Dull, D Farson, K M Zsebo, M H Finer.   

Abstract

TCR- and IgG-binding Fc receptors (Fc gamma R) mediate a variety of critical biologic activities including cytolysis via the structurally related zeta- and gamma-chains. In previous studies, we have described chimeric immune receptors (CIR) in which the ligand-binding domain of a heterologous receptor or Ab is fused directly to the cytoplasmic domain of the TCR zeta-chain. Such zeta-CIRs efficiently trigger cytotoxic function of both T and NK cells in a target-specific manner. In this report, we compared the ability of both zeta- and gamma-CIRs to activate the cytolytic function of two distinct classes of Fc gamma R-bearing effectors, NK cells and neutrophils. Mature neutrophils expressing zeta- and gamma-CIR were generated in vivo from murine hemopoietic stem cells following transplantation of syngeneic mice with retrovirally transduced bone marrow or in vitro from transduced human CD34+ progenitors following differentiation. Both zeta- and gamma-based CIRs were capable of activating target-specific cytolysis by both NK cells and neutrophils, although the zeta-CIR was consistently more efficient. The experimental approach described is a powerful one with which to study the role of nonlymphoid effector cells in the host immune system and permits the rational design of immunotherapeutic strategies that rely on harnessing multiple immune cell functions via CIR-modified hemopoietic stem cells or progenitors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9647246

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

2.  Gene-modified hematopoietic stem cells for cancer immunotherapy.

Authors:  Sarah Larson; Satiro N De Oliveira
Journal:  Hum Vaccin Immunother       Date:  2014-01-09       Impact factor: 3.452

3.  T Cell Reprogramming Against Cancer.

Authors:  Samuel G Katz; Peter M Rabinovich
Journal:  Methods Mol Biol       Date:  2020

Review 4.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

5.  Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.

Authors:  A D Gritzapis; A Mamalaki; A Kretsovali; J Papamatheakis; M Belimezi; S A Perez; C N Baxevanis; M Papamichail
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 6.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

7.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Cynthia C Bartholomae; Marco Ranzani; Fabrizio Benedicenti; Lucia Sergi Sergi; Alessandro Ambrosi; Maurilio Ponzoni; Claudio Doglioni; Clelia Di Serio; Christof von Kalle; Luigi Naldini
Journal:  J Clin Invest       Date:  2009-03-23       Impact factor: 14.808

8.  Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.

Authors:  Satiro Nakamura De Oliveira; Christine Ryan; Francesca Giannoni; Cinnamon L Hardee; Irena Tremcinska; Behrod Katebian; Jennifer Wherley; Arineh Sahaghian; Andy Tu; Tristan Grogan; David Elashoff; Laurence J N Cooper; Roger P Hollis; Donald B Kohn
Journal:  Hum Gene Ther       Date:  2013-10       Impact factor: 5.695

9.  Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.

Authors:  John Maher
Journal:  ISRN Oncol       Date:  2012-12-09

10.  Systems model of T cell receptor proximal signaling reveals emergent ultrasensitivity.

Authors:  Himadri Mukhopadhyay; Shaun-Paul Cordoba; Philip K Maini; P Anton van der Merwe; Omer Dushek
Journal:  PLoS Comput Biol       Date:  2013-03-28       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.